Stimulant medications commonly prescribed for ADHD, such as Adderall and Vyvanse, work by boosting dopamine and norepinephrine levels in the brain, which helps enhance focus and reduce hyperactivity. However, recent research indicates that taking high doses of these medications may significantly elevate the risk of developing psychosis or mania. In this study, participants who used higher doses of these stimulants were five times more likely to experience such mental health symptoms.
Key Points
- Risk Link: A new study has identified a connection between elevated doses of certain ADHD medications and a heightened risk of psychosis or mania.
- Small Overall Risk: Despite this association, the overall risk remains low, and for many individuals, the benefits of these medications continue to outweigh the potential side effects.
- Doctor Consultation: Patients may consider discussing dosage levels and any concerns about mental health risks with their healthcare provider to ensure their treatment plan aligns with their health profile.
Over the past decade, prescriptions for adults with attention deficit hyperactivity disorder (ADHD) have risen significantly, with stimulant medications being a primary treatment approach. However, while stimulants like Adderall and Vyvanse are effective in managing ADHD symptoms, a recent study published in the American Journal of Psychiatry raises concerns about their potential risks. The study suggests that adults who take high doses of certain stimulant medications may face a fivefold increase in their risk of developing psychosis or mania.
Psychosis, a severe mental health condition, disrupts a person’s ability to discern reality from delusion, while mania causes elevated and sometimes extreme levels of energy, activity, and mood. The lead study author, Lauren Moran, MD, MPH, a psychiatrist and researcher at McLean Hospital, highlights the importance of monitoring these potential risks, especially given the rise in ADHD diagnoses and treatment. “This is a rare but serious side effect that patients, family members, and their doctors should be aware of whenever these medications are prescribed,” says Dr. Moran.
Dose-Related Risks and Recommendations
Dr. Moran’s study examined data from 2005 to 2019, focusing on young adults aged 16 to 35, a demographic most at risk for psychosis onset. By analyzing over 1,300 cases of psychosis or mania against roughly 2,800 control cases of other psychiatric conditions, the researchers found that those taking higher doses of amphetamine-based medications were at increased risk. For instance, individuals prescribed daily doses of 30 milligrams (mg) of dextroamphetamine or more — equivalent to about 40 mg of Adderall or 100 mg of Vyvanse — were most susceptible.
A notable finding from the study was that nearly 63% of those exposed to high-dose stimulant medications faced a heightened risk of psychosis or mania. For patients prescribed doses beyond 30 mg, this risk escalated to 81%. “Our findings suggest that clinicians can mitigate the risk of psychosis or mania by avoiding doses above 30 mg dextroamphetamine equivalents,” says Dr. Moran. “There were a couple of people in the study who were on 120 mg of Adderall a day — I just don’t understand why people are prescribing such high doses, honestly.” Dr. Moran’s findings raise critical questions for prescribers, emphasizing the need for caution when determining stimulant dosages.
Considering Methylphenidate as an Alternative
In exploring potential alternatives, the study also looked at the effects of methylphenidate, a stimulant found in medications like Ritalin and Concerta. Unlike amphetamines, methylphenidate was not associated with an increased risk of psychosis or mania, a finding that may be linked to the lower doses typically prescribed for this medication.
However, some experts caution against dismissing risks with methylphenidate entirely. James Ashworth, MD, medical director at the Huntsman Mental Health Institute, believes that high doses of methylphenidate could also potentially trigger psychosis. “The researchers didn’t really address methylphenidate much in this study,” says Dr. Ashworth, who was not part of the research team. “I think high doses of that drug might also precipitate psychosis.” While methylphenidate appears safer at standard doses, Dr. Ashworth’s observations underscore the need for careful dosage considerations across all stimulant medications.
Risk Assessment: Balancing Benefits and Side Effects
David Goodman, MD, director of the Adult Attention Deficit Disorder Center of Maryland and a psychiatry professor at Johns Hopkins, emphasizes that while the risk of psychosis from stimulants is real, it remains relatively minor in the larger picture of ADHD treatment. “This risk is still relatively minor,” says Dr. Goodman, who did not contribute to the study. “It’s not zero, but it should not be the factor that leads people to consider whether or not they should treat their ADHD with stimulant medications.” Dr. Goodman highlights the importance of stimulant medication for many ADHD patients, advising that the new findings should not deter people from seeking effective treatment.
Previous research led by Dr. Moran supports the notion that the overall risk of psychosis is low for most ADHD patients. A 2019 study involving more than 330,000 young people prescribed stimulant medication for ADHD found that only about 1 in 660 experienced new-onset psychosis. However, as the recent study shows, this risk does become more pronounced at higher dosages, suggesting that patients and doctors may benefit from ongoing conversations around optimal dosing strategies.
Why Stimulants Are Prescribed for ADHD
ADHD is characterized by persistent difficulties in maintaining focus, managing impulses, and regulating energy levels. This can lead to challenges in personal relationships, performance issues at work or school, and low self-esteem. Stimulant medications like amphetamines are effective because they increase levels of dopamine and norepinephrine, neurotransmitters that play a key role in attention and impulse control. By enhancing these chemicals in the brain, stimulants can alleviate many of the hallmark symptoms of ADHD, allowing individuals to improve focus, self-control, and overall quality of life.
The effectiveness of these drugs is well-documented, and for most patients, the benefits far outweigh the risks. However, Dr. Moran’s study brings to light the importance of careful dosing and the need for clinicians to consider individual patient profiles. While high-dose stimulants can be beneficial for some patients, they are not universally necessary and may, in some cases, increase the risk of severe side effects.
The Path Forward: A Cautious Approach to ADHD Medication
In light of these findings, a cautious approach to prescribing stimulant medications may be warranted. Dr. Moran’s recommendation to limit dosages could help mitigate risks, while open discussions between patients and healthcare providers may further optimize treatment plans. “This is about understanding the balance between efficacy and safety,” says Dr. Moran. Her insights, along with additional perspectives from experts like Dr. Goodman and Dr. Ashworth, point to the need for personalized ADHD care that respects each patient’s unique medical and psychological profile.
For patients and their families, this research underscores the importance of staying informed about potential risks and benefits. With ongoing advancements in ADHD research, there is hope that more tailored treatments will continue to emerge, offering effective and safe options for those living with ADHD.
Recommended For You
